DK2173349T3 - Antitumor-kombinationer med et VEGF-hæmmende middel og irinotecan - Google Patents

Antitumor-kombinationer med et VEGF-hæmmende middel og irinotecan

Info

Publication number
DK2173349T3
DK2173349T3 DK08827826.2T DK08827826T DK2173349T3 DK 2173349 T3 DK2173349 T3 DK 2173349T3 DK 08827826 T DK08827826 T DK 08827826T DK 2173349 T3 DK2173349 T3 DK 2173349T3
Authority
DK
Denmark
Prior art keywords
irinotecan
vegf inhibitor
tumor
combinations
tumor combinations
Prior art date
Application number
DK08827826.2T
Other languages
English (en)
Inventor
Marie-Christine Bissery
Marielle Chiron-Blondel
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38961256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2173349(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK2173349T3 publication Critical patent/DK2173349T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK08827826.2T 2007-07-05 2008-07-02 Antitumor-kombinationer med et VEGF-hæmmende middel og irinotecan DK2173349T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704868A FR2918279B1 (fr) 2007-07-05 2007-07-05 Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
PCT/FR2008/000943 WO2009024667A2 (fr) 2007-07-05 2008-07-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan

Publications (1)

Publication Number Publication Date
DK2173349T3 true DK2173349T3 (da) 2011-06-27

Family

ID=38961256

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08827826.2T DK2173349T3 (da) 2007-07-05 2008-07-02 Antitumor-kombinationer med et VEGF-hæmmende middel og irinotecan

Country Status (24)

Country Link
US (3) US20100160233A1 (da)
EP (1) EP2173349B1 (da)
JP (4) JP2010532335A (da)
KR (4) KR20180105261A (da)
CN (3) CN105833244A (da)
AR (1) AR067420A1 (da)
AT (1) ATE500829T1 (da)
AU (1) AU2008290442B2 (da)
BR (1) BRPI0812835B8 (da)
CA (1) CA2693152C (da)
CY (1) CY1111675T1 (da)
DE (1) DE602008005457D1 (da)
DK (1) DK2173349T3 (da)
ES (1) ES2362637T3 (da)
FR (1) FR2918279B1 (da)
HR (1) HRP20110432T1 (da)
IL (2) IL203132A (da)
MX (1) MX2009013950A (da)
PL (1) PL2173349T3 (da)
PT (1) PT2173349E (da)
RS (1) RS51777B (da)
RU (1) RU2471483C2 (da)
SI (1) SI2173349T1 (da)
WO (1) WO2009024667A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2344161B1 (en) * 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
US20130029909A1 (en) * 2009-09-15 2013-01-31 John Ryan Treatment of cancer
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
IL163820A0 (en) * 2002-03-01 2005-12-18 Pharmacia Italia Spa Crystalline polymorphic form of irinotecan hydrochloride
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CA2534197A1 (en) * 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy
MXPA06014689A (es) * 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives

Also Published As

Publication number Publication date
US20190275147A1 (en) 2019-09-12
BRPI0812835B1 (pt) 2020-09-08
CN103623392A (zh) 2014-03-12
AR067420A1 (es) 2009-10-07
AU2008290442B2 (en) 2013-06-27
AU2008290442A1 (en) 2009-02-26
FR2918279A1 (fr) 2009-01-09
PT2173349E (pt) 2011-06-02
IL203132A (en) 2015-09-24
JP2019006785A (ja) 2019-01-17
BRPI0812835A2 (pt) 2014-12-09
JP2017052789A (ja) 2017-03-16
MX2009013950A (es) 2010-03-09
DE602008005457D1 (de) 2011-04-21
RU2010103781A (ru) 2011-08-10
FR2918279B1 (fr) 2010-10-22
IL240965A0 (en) 2015-10-29
US20140127202A1 (en) 2014-05-08
KR20150048910A (ko) 2015-05-07
CA2693152C (fr) 2019-02-26
HRP20110432T1 (hr) 2011-07-31
ATE500829T1 (de) 2011-03-15
CN105833244A (zh) 2016-08-10
WO2009024667A3 (fr) 2009-04-23
JP2014240422A (ja) 2014-12-25
EP2173349B1 (fr) 2011-03-09
EP2173349A2 (fr) 2010-04-14
KR20180105261A (ko) 2018-09-27
CY1111675T1 (el) 2015-10-07
PL2173349T3 (pl) 2011-08-31
ES2362637T3 (es) 2011-07-08
WO2009024667A2 (fr) 2009-02-26
CN101686975A (zh) 2010-03-31
SI2173349T1 (sl) 2011-06-30
KR20160079918A (ko) 2016-07-06
CA2693152A1 (fr) 2009-02-26
JP2010532335A (ja) 2010-10-07
KR20100031123A (ko) 2010-03-19
BRPI0812835B8 (pt) 2021-05-25
US20100160233A1 (en) 2010-06-24
RS51777B (en) 2011-12-31
RU2471483C2 (ru) 2013-01-10

Similar Documents

Publication Publication Date Title
DK2173349T3 (da) Antitumor-kombinationer med et VEGF-hæmmende middel og irinotecan
DK2376791T3 (da) Afstandsindretning og fastgørelsesindretning med afstandsindretning
CY2017016I1 (el) Αναστολεις πρωτεασωματος
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2185552T3 (da) Dipeptoid-prodrugs og anvendelse heraf
DK2108006T3 (da) Bindemidler og materialer lavet dermed
DK2393528T3 (da) Kateterindretning med et kateter og en aktiveringsindretning
DK2370224T3 (da) Rund endefræser og indsats
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
DK3092901T3 (da) Quinolonanaloger og fremgangsmåder relateret dertil
DK2172515T3 (da) Gummiforbindelse og støbt artikel
DK2064222T3 (da) Benzyliske glycosid-derivater og fremgangsmåder til anvendelse deraf
ATE509020T1 (de) 3-cyano-4-(4-tetrahydropyranphenyl)pyridin-2- onderivate
DK2482871T3 (da) Anti-bolus-kontrol metode og tilsvarende enhed
DK2146786T3 (da) Målanordning
DK2106215T3 (da) Brød med forhøjet arabinoxylo-oligosaccharid-indhold
NO20061669L (no) SmartPlug with centralizer means
DK2130392T3 (da) Konfigurabel indretning og fremgangsmåde
DK2192933T3 (da) Materialer til oftalmologisk og ortorhinolaryngologisk anordning
DK2194831T3 (da) Rengøringsværktøj og rengøringsindretning med et sådant rengøringsværktøj
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
SI2222981T1 (sl) Pogonska sredstva in verižni pogon
DK2295646T3 (da) Boreindretning og borefremgangsmåde